TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07743164: A Phase 3, Open-Label, Multicenter, Randomized Study of Raludotatug Deruxtecan (MK-5909, R-DXd) With or Without Bevacizumab Versus Standard-of-Care Platinum-Based Doublet Chemotherapy With or Without Bevacizumab in Parti

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 646 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07743164 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07743164 Rescue Dossier →